entertainment -WSS

entertainment

author：comprehensive 2025-09-27 22:48:40 - browse：3956

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： With fresh data, a dynamic duo powers Eli Lilly to new heights

knowledge

WSS

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Neutralizing antibodies against HIV shows promise in children

Florida officials tell state schools to teach AP Psychology 'in its entirety'

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

focus

entertainment

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

UPS workers' union leader explains what's at stake as strike edges closer

Medicare details structure of new drug price negotiation program

FDA scientists endorse Pfizer/BioNTech Covid

The cancer drug shortage isn’t new — and neither are the solutions

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

Activists slam private health insurers over coverage restrictions

Drinking water from half of US faucets contains PFAS: Study

Bright Health sells Medicare Advantage business to Molina

Florida officials tell state schools to teach AP Psychology 'in its entirety'

explore

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Trump seeks lengthy delay of classified docs trial, citing upcoming election

How to ethically and practically extend health care to all

Titanic submersible victims' family mourns: 'Enormous tragedy and devastation'

North Korean leader's powerful sister says warplanes repelled US spy plane

Neutralizing antibodies against HIV shows promise in children

explore

knowledge

knowledge

leisure time